HeartWare International (ASX:[[ticker:HIN]]), a small Framingham, MA-based developer of an implant used to keep the heart beating, has agreed to be sold to Pleasanton, CA-based medical devices firm Thoratec (NASDAQ:[[ticker:THOR]]) in a half stock, half cash deal valued at $282 million, according to Thoratec. The deal is expected to close in the second half of 2009. HeartWare CEO Doug Godshall, a former group president at Natick, MA-based medical devices giant Boston Scientific (NYSE:[[ticker:BSX]]), moved HeartWare’s main corporate office from Australia to Massachusetts after he took the reins at the firm in 2006.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
